The treatment of the germinal center lymphomas, diffuse large B cell (DLBCL) and follicular lymphoma, has changed little beyond the introduction of immunochemotherapies. However, there exists a substantial group of patients within both diseases for which improvements in care will involve appropriate tailoring of treatment.
INTRODUCTION
The treatment of the two most common forms of germinal center non-Hodgkin lymphomas (NHLs), diffuse large B cell (DLBCL) and follicular lymphoma, was revolutionized by the addition of rituximab to chemotherapeutic regimens (R-CHOP). Over half of DLBCL patients are now curable by R-CHOP, while despite follicular lymphoma being considered an incurable disease, the majority of follicular lymphoma patients live for upward of 15 years. Beyond these successes, prognosis remains poor for a third of relapsed-refractory DLBCL patients, and for a quarter of follicular lymphoma patients who are prone to early relapse and/or transformation to a more aggressive lymphoma (tFL). There is renewed optimism that the molecular characterization of these diseases will allow for the prediction of high-risk patients and the tailoring of treatments based on a patient's molecular profile. In this review, we will focus on the prognostic strategies to identify high-risk patients and the progress now being made in developing targeted therapies for these germinal center lymphomas.
THE MOLECULAR LANDSCAPE OF GERMINAL CENTER LYMPHOMAS
The introduction of next-generation sequencing (NGS) sparked a dramatic increase in our understanding of the molecular events that drive germinal center lymphomas. There are now well over 200 recurring gene mutations described, although only a minority occur in greater than 5-10% of patients. The significance of gene translocations targeting MYC, BCL2 and BCL6 is all well established, as is the recognition of widespread disruption of the epigenome, predominantly driven by somatic mutations within KMT2D, CREBBP, EZH2 and linker histones [1,2 & ,3-10,11
greater degree of genetic heterogeneity than follicular lymphoma, and can be readily divided into at least two major subtypes based on the 'cell of origin' (COO): germinal center B cell (GCB)-like and activated B cell (ABC)-like DLBCL [14, 15] . The ABC-DLBCL subtype has the poorer prognosis by far [40% 3-year overall survival (OS)] and is typified by constitutive NF-kB activation and signaling driven by somatic mutations in the B cell receptor (BCR) and NF-kB pathway genes (CARD11, CD79B, MYD88 and TNFAIP3) [16] [17] [18] [19] [20] , whereas GCB-DLBCL has a better prognosis (80% 3-year OS) and more closely resembles follicular lymphoma. Although there are specific gene mutations that are enriched in each group, the overall landscape is complex and contrary to earlier expectations, BCR and NF-kB pathway mutations also arise in GCB-DLBCL and follicular lymphoma, albeit at a lower frequency [2
IDENTIFYING HIGH-RISK DIFFUSE LARGE B CELL PATIENTS
Overall, progress has been sluggish in discriminating high from low-risk patients within the distinct COO entities with the exception of the 'high-grade B cell lymphomas, with MYC and BCL2 and/or BCL6 rearrangements', also known as double and triplehit lymphomas, and the 'double-expressors' that highly express both BCL2 and MYC in the absence of rearrangements [21, 22] . Both groups demonstrate an aggressive phenotype associated with poor outcomes and therefore are a high priority for clinical intervention. Nevertheless, we are likely to see an acceleration in improved prognostic models and refined patient subsets in the foreseeable future, as our understanding of the landscape of coding aberrations in DLBCL nears completion. A monumental study by Reddy et al. [11 && ] has set the pace with an extensive analysis of 1001 newly diagnosed DLBCL patients, integrating mutational profiling, gene expression analysis and clinical information, which has offered novel insights into combinatorial factors influencing outcome for near enough the first time.
Although many of these observations will require validation, (e.g. KLH14 mutations being predictive of high-risk ABC-DLBCL, and EZH2 mutations predicting low-risk GCB-DLBCL), the size and depth of the data allowed the authors to devise an encouraging prognostic multivariate genomic risk model. Such large collaborative studies will undoubtedly be the benchmark for future studies and provide a framework for developing prospective risk-adapted strategies for DLBCL.
A NEW ERA IN FOLLICULAR LYMPHOMA STRATIFICATION?
Molecular stratification of follicular lymphoma has lagged behind DLBCL, with the COO classification first described nearly 20 years ago [14] . Traditional attempts at risk stratification in the era of immunochemotherapy have been based on clinical parameters such as the Follicular Lymphoma International Prognostic Index (FLIPI) scores, the FLIPI and FLIPI-2, but are for the most part fairly ineffective tools for directing management decisions [23, 24] . Although molecular prognostication has long been opined as having more potential, it is only of late that we are seeing inroads into the development of tools capable of navigating the clinical heterogeneity within follicular lymphoma and able to predict high-risk patients. The earliest studies by the Lymphoma/Leukemia Molecular Profiling Project stratified follicular lymphoma based on the patterns of two gene signatures associated with T cell and myeloid cell infiltration [25] . However, we may well have turned the corner with the recent development of the m7-FLIPI, a clinico-genetic risk model that incorporates the clinical features of the FLIPI and the mutational status of seven genes (EP300, FOXO1 CREBBP, CARD11, MEF2B, ARID1A, EZH2) [26] , and an alternative prognostic strategy based on the expression of 23 genes (23G model) from both the tumor and microenvironment [27 && ]. It is likely that these models will continue to evolve as they are impacted by treatment changes, such as the move toward chemotherapy-free interventions, and we need to lay the groundwork for these changes by developing the infrastructure to enable head-to-head comparisons and reach a consensus on the level of discrimination needed to guide treatment, especially for an indolent disease such as follicular lymphoma where a high prognostic accuracy is necessary.
UPFRONT PROGNOSTICATION VERSES DYNAMIC DISEASE MONITORING
All of the aforementioned clinical and molecular prognostic strategies are based on upfront testing and prognostication. However, sampling of a single
KEY POINTS
Specific subgroups of high-risk DLBCL patients within the COO entities are now recognized.
Notable advances made in identifying high-risk follicular lymphoma with the development of novel molecular prognostication tools.
Ibrutinib and tazemetostat are showing preferential benefit in specific populations of germinal center lymphoma patients.
site at diagnosis fails to account for the temporal [1, [28] [29] [30] [31] and spatial heterogeneity [32] observed in germinal center lymphomas. The assessment of cellfree DNA (cfDNA) from plasma samples offers the possibility of more effectively sampling the heterogeneity in germinal center lymphomas, and dynamically monitoring changes in prognostic markers and actionable targets in a minimally invasive manner. Although it has not been widely applied so far, early studies have suggested a number of possible applications including the ability to classify the COO in DLBCL patients and to predict transformation of follicular lymphoma [33] [34] [35] . In an era where there is a headlong shift away from excision biopsies, it is likely that noninvasive cfDNA-based diagnostics and prognostics will have a significant future role within germinal center lymphomas.
IBRUTINIB PREFERENTIALLY BENEFITS ACTIVATED B CELL-DIFFUSE LARGE B CELL PATIENTS
Running in tandem with efforts at exploiting genetic data for defining risk, access to genetic profiles is also pointing the way toward novel therapies. Ibrutinib, which inhibits the BTK enzyme responsible for propagating prosurvival signals from the BCR, which is constitutively active in ABCDLBCLs (Fig. 1) [36] , has proved to be revolutionary in the treatment of chronic lymphocytic leukemia [37] , and accumulating data suggest that it may be efficacious in poor-risk, BCR/NF-kB-dependent ABC-DLBCL patients. In a phase I/II trial of 80 patients, single-agent ibrutinib was well tolerated and had an overall response rate (ORR) of 37% in ABC-DLBCL, compared to only 5% in GCB-DLBCL patients [36] , and it is encouraging that all non-GCB patients achieved complete remission in a phase I study examining ibrutinib in combination with rituximab-based chemotherapy [38] . Following the success of these trials, ibrutinib is being tested in several phase III trials for ABC-DLBCL, which includes combination with R-CHOP for newly diagnosed ABC-DLBCL patients (NCT01855750), and in relapsed/refractory ABC-DLBCL patients undergoing stem cell transplant (NCT02443077).
In follicular lymphoma, single-agent ibrutinib was shown to only have modest activity [39] , despite evidence that BCR signaling has a role in follicular lymphoma pathogenesis [40] [41] [42] [43] [44] . Combination studies with rituximab have improved on the singleagent outcomes [45] , but it seems sensible that upfront selection should be a feature of future trials, with evidence that MYD88 mutations are associated with a positive outcome in DLBCL [36] , whereas CARD11 mutations appear to influence ibrutinib resistance in follicular lymphoma [39] .
EZH2 INHIBITORS MAY SELECTIVELY BENEFIT EZH2-MUTANT PATIENTS
The recent recognition of gain-of-function mutations in EZH2 demonstrates the speed by which discoveries relating to the molecular pathogenesis of a disease are translatable into potential clinical benefit. EZH2 is a histone methyltransferase that acts as the catalytic subunit of the polycomb repressor complex 2 and catalyzes repressive monomethylation, dimethylation and trimethylation of the histone 3 lysine 27 (H3K27) residue. In germinal center lymphomas, its important role in regulating the normal germinal center reaction [46] is subverted by heterozygous mutations most commonly altering tyrosine 646 (Y646) within the catalytic SET domain [47] . These gain-of-function mutations alter the catalytic activity of the mutant EZH2 enzyme so that it preferentially catalyzes the conversion of H3K27me1 into the strongly repressive H3K27me2/3 marks, whereas the wild-type protein continues to deposit H3K27me1 [48] .
Selective EZH2 inhibitors have been developed by Epizyme (EPZ6438, tazemetostat [49] ), GlaxoSmithKline (GSK126 [50] ) and Constellation Pharmaceuticals (CPI-1205 [51] ), with preclinical data indicating that these compounds are generally more active in mutant cell lines and able to reactivate genes repressed or silenced by mutant EZH2 [49] [50] [51] . Phase I/II clinical trials have now been launched for all of these compounds to examine their efficacy for NHL with recent interim data suggesting that tazemetostat is efficacious for EZH2-mutated follicular lymphoma patients (92% ORR in mutant vs. 26% in wild-type) and to a lesser extent in DLBCL (29% ORR in mutant vs. 15% in wild-type) [52] . Altogether, these results are encouraging and highlight the attractions of precision medicine although given that EZH2 mutations have been provisionally linked with better outcomes in germinal center lymphomas [26, 53] thus or therefore EZH2 inhibitors will need to demonstrate significant benefit over the current standard of care to justify their use as a targeted therapy in this subgroup of patients.
REVISITING MTOR INHIBITORS IN THE LIGHT OF RECENT DEVELOPMENTS
It is also possible that armed with new insights into the genetic basis of germinal center lymphomas, we can revisit historical clinical studies and explore opportunities for precision treatments. Inhibition of the mTOR (mammalian target Of rapamycin) pathway, previously evaluated in follicular lymphoma, serves as a notable example with two phase II trials of second-generation mTOR inhibitors, temsirolimus and everolimus, demonstrating promising results in multiply relapsed cohorts (ORR 53.8% [54] and ORR 38% [55] , respectively). These trials, however, were performed before the discovery of unique mutations of the RRAGC and the V-ATPase ATP6V1B2 and ATP6AP1 genes in around 30% of follicular lymphoma patients, enforcing mTORC1 activation [4, 56, 57] . With the spectrum of different molecular lesions that we are now aware of in germinal center lymphomas, there may be opportunities to reexamine previously trialed agents, to determine whether events such as mTOR pathway mutations are predictive of response. Equally this also reaffirms the need and value of rigorously collecting biopsy material as part of clinical trials for later correlative studies.
NEW STRATEGIES TO REVERSE THE EARLY LOSS OF CREBBP IN PRECURSOR CELLS
Given the frequency and recognition of CREBBP mutations as one of the earliest events in germinal center lymphomas [8] [9] [10] 11 && , [58] [59] [60] , and their widespread role in promoting germinal centerlymphoma development [4, [58] [59] [60] [61] [62] , the successful targeting of these lesions would offer an exciting new therapy with the potential to eradicate diseasepropagating cells. Indeed, phylogenetic analysis has revealed that overt follicular lymphoma, and subsequent relapses of the disease, is likely to develop from long-lived premalignant cells known as common progenitor cells, which are believed to be t(14;18)-positive and typically contain mutations within the histone regulatory genes CREBBP and KMT2D [1, [3] [4] [5] [63] [64] [65] [66] . There is a persuasive argument to suppose that inhibition of the histone deacetylase (HDAC) enzymes that normally oppose CREBBP by removing acetylation marks could mitigate the deep-rooted loss of histone acetyltransferases CREBBP and EP300. Overall, while pan-HDAC inhibitors have demonstrated efficacy in germinal center lymphomas [67] [68] [69] , the occurrence of significant toxicities, alongside the absence of a biomarker and an unclear mechanism of action, has limited progress beyond phase II trials. Their fortunes may well change in the future, with recent studies exploring the relationship between CREBBP mutations and HDAC isoforms indicating that HDAC3 opposes the activity of CREBBP at enhancers and hyper-represses these enhancers following the loss of CREBBP, resulting in an increased dependency on HDAC3 for survival [58] . Targeting the HDAC3 isoform thus offers a potential therapeutic strategy with the promise of reactivating CREBBPregulated genes while minimizing toxicity associated with pan-HDAC inhibitors.
CONCLUSION
Our understanding of the biology of the germinal center lymphomas has increased dramatically with the introduction of NGS, and our ability to parallel clinical and molecular heterogeneity. There are signs that we are on the edge of a new precision era for germinal center lymphomas. Several new upfront prognostic strategies have been published for follicular lymphoma, and the seminal study by Reddy et al. examining 1001 DLBCL patients has highlighted the need for similar large-scale, multiinstitutional collaborative studies across all lymphomas, including follicular lymphoma. Furthermore, cfDNA assessment has raised the possibility of undertaking dynamic disease monitoring accounting for spatial and temporal heterogeneity and forecasting the trajectory of the tumor's evolution in real time.
The identification of therapeutics targeted toward specific molecular lesions has also seen significant advances in germinal center lymphomas, including the observations of selective benefit for ibrutinib in ABC-DLBCL and tazemetostat in EZH2 mutant follicular lymphoma. The challenge now is to establish how best to combine upfront prognostication with dynamic monitoring, while retaining practicality, to ensure that patients receive the best possible treatment.
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